Stay Engaged
News & updates.
Welcome to our News & Updates page, where you can find the latest information and insights on our journey towards Here, we share exciting news, scientific breakthroughs, and updates on our ongoing projects. Stay connected with us to stay informed about the latest developments, upcoming events, and important announcements. Explore our news articles and discover how we are making significant strides towards improving the lives of those affected by Parkinson’s disease.
30.09.2023 – science
The first scientific paper from Macrobian Biotech is now published
Our first scientific research paper is published in the Journal of Neurochemistry. Our work titled “Tyrosine hydroxylase phosphorylation is under the control of serine 40” delves into the regulation of the rate-limiting enzyme in dopamine synthesis: Tyrosine Hydroxylase.
16.11.2022 – EVENT
Macrobian Biotech to Present at HIHR & EIT Health Pitch Event 2022 in Eindhoven
On Wednesday, November 16th, Macrobian Biotech will be in attendance at the HIHR & EIT Health pitch event, held in Eindhoven, the Netherlands, where they will also be presenting.
28.01.2021 – patent
Macrobian Biotech's Second Patent Now Publicly Available
We are thrilled to announce the release of our second patent focused on advancing the treatment of Parkinson’s disease. Titled ‘Use of a PDE11 or PDE2 Inhibitor for the Treatment of Parkinson’s Disease,’ this patent encompasses innovative means and methods for addressing the condition. In certain embodiments, it involves the utilization of a PDE2 inhibitor, a PDE11 inhibitor, or a combination thereof, along with the possibility of a GUCY2C agonist. This achievement represents another significant milestone in our ongoing commitment to improving the lives of individuals affected by Parkinson’s.
17.09.2020 – Media
Macrobian Biotech's founders featured in Amsterdam Neuroscience Magazine 2020
Macrobian Biotech’s founders, Dr. Lars van der Heide and Professor Dr. Marten Smidt, are featured in the latest edition of Amsterdam Neuroscience Magazine. The magazine showcases their journey as entrepreneurs and highlights their significant contributions to the field of neuroscience. Driven by their collaborative efforts that began in 2002, the founders discuss how their research and their mission to bridge the gap between scientific discoveries and practical applications led to the creation of Macrobian Biotech. To learn more about their story, read pages 26 and 27 of Amsterdam Neuroscience Magazine 2020.
09.01.2020 – patent
Macrobian Biotech's First Patent Now Publicly Available
We are pleased to announce that our patent, titled ‘Specific Increase of Dopamine Synthesis Through Targeting of the Guanylate Cyclase 2C Receptor,’ is now accessible to the public. This patent encompasses novel approaches and techniques for the treatment of Parkinson’s disease. Notably, it involves the utilization of a GUCY2C agonist in certain methodologies. Additionally, the patent highlights the significance of test systems and cells in identifying potential candidate compounds for Parkinson’s disease treatment.
14.03.2019 – Media
Macrobian biotech's Approach featured in the Pharmaceutical Patent Analyst
Macrobian Biotech’s novel approach to treating Parkinson’s disease has garnered recognition in a recent issue of Pharmaceutical Patent Analyst (Vol. 8, No. 1), which was published online on March 14, 2019. The innovative approach, outlined in Macrobian’s patent (WO/2018/160067), was prominently featured and described as “a truly novel alternative” to current treatment methods for Parkinson’s disease. This acknowledgment in the Pharmaceutical Patent Analyst magazine highlights the pioneering nature of Macrobian’s work in addressing the challenges of Parkinson’s disease.
14.09.2017 – News
UvA spin-off Macrobian Biotech Secures Seed Investment
The University of Amsterdam (UvA)’s Faculty of Science, UvA Ventures Holding B.V. and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop medicine for the treatment of Parkinson’s disease.